| Entry |
|
|---|
| Name |
Treprostinil (JAN/USAN/INN);
Remodulin (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C23H34O5
|
|---|
| Exact mass |
390.2406
|
|---|
| Mol weight |
390.5131
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01712 Antiplatelet agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG01810 Prostacycline derivative
Other
DG01961 Prostaglandin derivative
DG01810 Prostacycline derivative
DG02573 Prostanoid derivative
DG01961 Prostaglandin derivative
DG01810 Prostacycline derivative
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
|
|---|
| Remark |
| Therapeutic category: | 2190 |
| Product (DG00161): | D06213<JP/US> |
|
|---|
| Efficacy |
Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist |
|---|
| Disease |
Pulmonary arterial hypertension [DS: H01621] |
|---|
| Comment |
Prostacycline derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP2C8 [HSA: 1558]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07228 | Eicosanoid receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC21 Treprostinil
D06213 Treprostinil (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Pulmonary Antihypertensives
Prostacyclin Vasodilators
Treprostinil
D06213 Treprostinil (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D06213 Treprostinil (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Prostacyclin
PTGIR
D06213 Treprostinil (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06213
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06213
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06213
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06213
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 28
1 C1x C 18.2700 -24.7100
2 C1y C 19.0400 -25.9000
3 C1y C 20.3700 -25.4800
4 C1y C 20.3700 -24.0800
5 C1y C 19.0400 -23.5900
6 C1b C 21.5600 -26.1800
7 C1b C 22.7500 -25.4800
8 C1c C 23.9400 -26.1800
9 C1b C 25.1300 -25.4800
10 O1a O 23.9400 -27.5800
11 C1b C 26.3200 -26.1800
12 C1b C 27.5100 -25.4800
13 C1b C 28.7000 -26.1800
14 C1a C 29.8900 -25.4800
15 O1a O 18.5500 -27.2300
16 C1x C 21.4200 -23.1700
17 C8y C 21.2100 -21.7700
18 C8y C 19.8800 -21.2800
19 C1x C 18.8300 -22.1900
20 C8x C 22.2600 -20.9300
21 C8x C 22.0500 -19.5300
22 C8x C 20.7200 -19.0400
23 C8y C 19.6700 -19.9500
24 O2a O 18.4800 -19.2500
25 C1b C 17.2900 -19.9500
26 C6a C 16.1000 -19.2500
27 O6a O 14.9100 -19.9500
28 O6a O 16.1000 -17.8500
BOND 30
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 1 5 1
6 3 6 1 #Up
7 6 7 1
8 7 8 1
9 8 9 1
10 8 10 1 #Down
11 9 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 2 15 1 #Down
16 4 16 1 #Down
17 16 17 1
18 17 18 1
19 18 19 1
20 5 19 1 #Down
21 17 20 2
22 20 21 1
23 21 22 2
24 22 23 1
25 18 23 2
26 24 23 1
27 24 25 1
28 25 26 1
29 26 27 1
30 26 28 2
|
|---|
